Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, has confirmed its total voting rights figure as at 30 October 2026. The company's issued share capital consists of 1,074,193,695 ordinary shares of 1.5p each, all carrying equal voting rights with no shares held in treasury. The disclosure is made in accordance with FCA Disclosure and Transparency Rule 5.6.1 and provides shareholders with the denominator required to assess whether they must notify changes to their interest in the company.

Key Points

  • Shield Therapeutics plc (LSE: STX) — commercial-stage specialty pharmaceutical company focused on iron deficiency
  • Total issued share capital confirmed at 1,074,193,695 ordinary shares of 1.5p each, all with equal voting rights
  • No shares are held in treasury; disclosure dated 30 October 2026 under FCA DTR 5.6.1
  • Investors should watch whether this figure changes in future monthly disclosures, which may signal new share issuances

Shield Therapeutics Discloses 1,074,193,695 Ordinary Shares Under FCA Transparency Rules

The announcement confirms that Shield Therapeutics' entire issued share capital of 1,074,193,695 ordinary shares of 1.5p each remains in circulation, with no shares held in treasury. This figure serves as the official denominator that shareholders and institutional investors must use when calculating whether their holding crosses a notifiable threshold under the FCA's Disclosure Guidance and Transparency Rules. Such monthly disclosures are a routine regulatory requirement for UK-listed companies but remain important reference points for tracking any changes in capital structure over time.

ACCRUFeR® Positioned as the Number-One Branded Prescription Oral Iron in the US Market

Shield Therapeutics markets ACCRUFeR®/FeRACCRU® (ferric maltol), described in the announcement as the first and only FDA-approved oral iron therapy to treat iron deficiency with or without anaemia. According to IQVIA Xponent PlanTrak data cited in the announcement, ACCRUFeR® is currently the number-one branded prescription oral iron in the US market. The company has launched the product in the US, including for paediatric patients aged ten years and older, targeting a market that the announcement states affects approximately 20 million people in the US and represents a $2.3 billion opportunity.

Global Licensing Network Extends FeRACCRU® Reach Across Six International Territories

Beyond the US, Shield has licensed commercialisation rights to partners across multiple territories. FeRACCRU® is sold in the UK and European Union by Norgine B.V., with coverage extending to Australia and New Zealand. Further licensing agreements are in place with Kye Pharmaceuticals for Canada, Beijing Aosaikang Pharmaceutical for China, Hong Kong, Macau and Taiwan, Korea Pharma for the Republic of Korea, and Medleap Pharma for Japan. The announcement states that ACCRUFeR®/FeRACCRU® carries patent coverage until the mid-2030s, providing a defined period of intellectual property protection for the asset.

Ferric Maltol's Novel Absorption Mechanism Underpins Shield's Commercial Differentiation

ACCRUFeR®/FeRACCRU® is described in the announcement as a novel, stable, non-salt-based oral therapy with a distinct mechanism of absorption compared with other oral iron treatments. The company states the drug has demonstrated efficacy and tolerability across a range of clinical trials. Investors may be watching Shield's ability to sustain its market-leading branded position in the US while growing revenue from its international licensing network, particularly given the competitive dynamics of the broader iron deficiency treatment landscape and the company's reliance on a single core product.